EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation

Dong Ha Kim, Ho Cheol Kim, Kyungtaek Im, In-Jeoung Baek, Yun Jung Choi, Hyeonjeong Lee, Da-Som Kim, Chae Won Lee, JaeYi Jeong, Kyosun Ban, Sang-Yeob Kim, Wonjun Ji und 7 weitere

European Respiratory Journal · 2025-06 · 65 (6) · 2400615

DOI: 10.1183/13993003.00615-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 09.01.2025. Verfasst von Dong Ha Kim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Macrophages, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Although a relationship between the growth arrest-specific 6 (GAS6)/anexelekto (AXL) pathway and pulmonary fibrosis has been suggested, the precise mechanisms and clinical implications of the AXL pathway in idiopathic pulmonary fibrosis are still unclear.

Methods

Constitutive and conditional AXL-knockout mice were generated and injected with bleomycin to induce pulmonary fibrosis. The expression of AXL and macrophage subtypes in bleomycin-injected mice and patients with idiopathic pulmonary fibrosis was analysed using flow cytometry. The therapeutic effects of the AXL inhibitors were examined.

Results

AXL-deficient mice were resistant to bleomycin-induced pulmonary fibrosis and had a lower degree of M2-like macrophage differentiation than wild-type mice. Interestingly, AXL expression in monocytes was enhanced according to the progression of bleomycin-induced pulmonary fibrosis, and these results were especially prominent in lymphocyte antigen 6C (Ly6C) high monocytes. Gene silencing or inhibitor treatment with AXL inhibited the differentiation of M2-like macrophages during bone marrow-derived macrophage differentiation. These results were confirmed through experiments using AXL fl/fl LysMCre+ mice and systems with depletion and reconstitution of macrophages. In line with these results, patients with severe idiopathic pulmonary fibrosis had high AXL expression in monocytes, high GAS6 levels and an enhanced population of M2-like macrophages compared to those with mild idiopathic pulmonary fibrosis. Lastly, treatment with AXL inhibitors ameliorated bleomycin-induced pulmonary fibrosis and improved survival rates.

Conclusions

The AXL pathway in classical monocytes contributes to pulmonary fibrosis progression through the induction of M2-like macrophage differentiation. Therefore, targeting AXL may be a promising therapeutic option for pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Protein-Tyrosine KinasesProto-Oncogene ProteinsMacrophagesIdiopathic Pulmonary FibrosisPulmonary FibrosisAnimalsMiceAxl Receptor Tyrosine KinaseBleomycinHumansMice, KnockoutCell DifferentiationIntercellular Signaling Peptides and ProteinsMaleMonocytesMice, Inbred C57BLDisease Models, AnimalFemaleGrowth Arrest-Specific Protein 6

Substanzen

Receptor Protein-Tyrosine KinasesProto-Oncogene ProteinsAxl Receptor Tyrosine KinaseBleomycinIntercellular Signaling Peptides and ProteinsGrowth Arrest-Specific Protein 6AXL receptor tyrosine kinase, mouseAXL protein, human

Autor:innen und Institutionen

  • Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • D.H. Kim, H.C. Kim and K. Im contributed equally to this work.
  • Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Biochemistry and Molecular Biology, Brain Korea 21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Förderung

  • Ministry of Health and Welfare
  • National Research Foundation of Korea

Zitieren

APA

Kim, D. H., Kim, H. C., Im, K., Baek, I. J., Choi, Y. J., Lee, H., Kim, D. S., Lee, C. W., Jeong, J., Ban, K., Kim, S. Y., Ji, W., Lee, J. C., Kim, H. Y., Lee, Y., Yang, Y., Yun, M., Choi, C. M., & Rho, J. K. (2025). Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation. European Respiratory Journal, 65(6), 2400615. https://doi.org/10.1183/13993003.00615-2024

Vancouver

Kim DH, Kim HC, Im K, Baek IJ, Choi YJ, Lee H, et al. Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation. European Respiratory Journal. 2025;65(6):2400615. doi:10.1183/13993003.00615-2024

BibTeX
@article{Kim2025,
  author = {Kim, Dong Ha and Kim, Ho Cheol and Im, Kyungtaek and Baek, In-Jeoung and Choi, Yun Jung and Lee, Hyeonjeong and Kim, Da-Som and Lee, Chae Won and Jeong, JaeYi and Ban, Kyosun and Kim, Sang-Yeob and Ji, Wonjun and Lee, Jae Cheol and Kim, Hyun-Yi and Lee, Yoonji and Yang, Yeongin and Yun, Miyong and Choi, Chang Min and Rho, Jin Kyung},
  title = {Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {6},
  pages = {2400615},
  doi = {10.1183/13993003.00615-2024}
}
Kostenlos starten →